What development stage is Okyo Pharma Limited Npv described as in the update?

OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing urcosimod, a topical therapy for neuropathic corneal pain. The drug holds Fast Track designation and is the first investigational treatment specifically targeting this chronic ocular condition.

Sector: Biotech

Insight

What feedback did the FDA provide in the July 8, 2026 Type D meeting about the NEPTUNE trial design?

In a July 8, 2026 FDA Type D meeting, feedback validated the NEPTUNE trial design, while the agency continued its review.

Updated 6 Oct 2026

Insight

Does the update on Okyo Pharma Limited Npv include valuation or operating ratios such as P/E or EV/EBITDA?

No. The update provides no valuation or operating ratios (P/E, EV/EBITDA, margins) nor the underlying financials needed to calculate them.

Updated 8 Jul 2026

Insight

Who enrolled the first patients in OKYO Pharma’s Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain?

OKYO Pharma reported that Dr. Melissa Toyos enrolled the first patients at the Toyos Clinic in Nashville, Tennessee.

Updated 6 Oct 2026

Insight

What does Okyo Pharma plan to seek from the FDA for urcosimod on July 8, 2026?

On July 8, 2026, Okyo Pharma said it intends to seek FDA Breakthrough Therapy Designation for urcosimod.

Updated 6 Oct 2026

Insight

Where is Okyo Pharma Limited Npv conducting its Phase 3 NEPTUNE trial?

Okyo Pharma Limited Npv is conducting its Phase 3 NEPTUNE trial in the United States and Europe, with additional sites planned in Italy, Spain and France.

Updated 6 Oct 2026

Identifiers

Ticker: OKYO

Learn more on:

Official site

Timeline

Okyo Pharma

OKYO Pharma enrolls first patients in Phase 3 neuropathic corneal pain trial

OKYO Pharma accelerates urcosimod into Phase 3 after FDA validates trial design

More in Biotech

Genflow wins Japanese patent allowance for SIRT6 therapy

Scancell widens annual loss

Sareum signals intention to launch equity capital raise

Poolbeg Pharma secures South Korean patent for POLB 001

Avacta raises £12.5m in placing and subscription

Health & Bio Today: Fusion Antibodies refreshes platform after margin turnaround, Molecule Group

Fusion Antibodies relaunches website to sharpen customer focus

Cardiogeni shares suspended on delayed annual accounts

Imaging Biometrics builds US pipeline, rebrands core platform as IB Vista

Eden Research wins US label expansion for Mevalone

GENinCode revenue halves as NHS cutbacks bite

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer